To investigate the clinical effect of Huanglian Qingjie Granule combined with improved combination therapy on spleen and stomach damp-heat type patients with chronic gastritis whose eradication of Helicobacter pylori (Hp) failed.

The research subjects were 82 patients with chronic gastritis of the spleen and stomach damp-heat type who failed the initial eradication of Hp and were admitted to Zhengzhou Hospital of Traditional Chinese Medicine from January 2023 to April 2025. They were divided into two groups according to a randomized, parallel controlled design: the control group and the treatment group, with 41 patients in each group. The control group was treated with modified double therapy, and the treatment group was treated with Huanglian Qingjie Granule on the basis of the control group. Both groups were treated for 1 month. The clinical efficacy of the two groups was compared. The Hp clearance of the two groups was compared one month after treatment. The TCM syndrome scores of the two groups were compared before treatment and one month after treatment. The levels of inflammatory factors were compared between the two groups before and 1 month after treatment.

Compared with the control group, the total effective rate was significantly higher in the treatment group (P < 0.05). Compared with control group, Hp clearance rate in treatment group was significantly higher (P < 0.05). Compared with the control group, the main symptom score and secondary symptom score of TCM syndrome score were significantly decreased in the treatment group one month after treatment (P < 0.05). Compared with the control group, the levels of tumor necrosis factor-α (TNF-α) and interleukin-1 β (IL-1β) were significantly decreased in the treatment group one month after treatment, and the level of interleukin-10 (IL-10) was significantly increased in the treatment group (P < 0.05).

The combination of Huanglian Qingjie Granules and the modified dual therapy can effectively enhance the clinical efficacy of patients with chronic gastritis of spleen and stomach damp-heat type who have failed Hp eradication, increase the Hp eradication rate of patients, improve their TCM syndrome score and inflammatory factor levels, and can be widely applied in clinical practice.

To investigate the effects of Kongsheng Zhenzhong Pill Modified Formula on cognitive function, inflammatory factor and Chinese medicine syndrome score in patients with cerebral small vessel disease (CSVD) with kidney deficiency, phlegm and stasis type.

A retrospective selection was made of 210 inpatients with CSVD (kidney deficiency and phlegm-stasis type) from the Department of Neurology of Xi'an Hospital of Traditional Chinese Medicine from January 2020 to January 2025, among which 104 patients receiving conventional treatment were included in the basic group and 106 patients who received the modified formula of Kongsheng Zhenzhong Pill Modified Formula on the basis of conventional treatment were included in the study group, and the efficacy of the 2 groups, cognitive function [Montreal Scale (MoCA) and the Simple Mental State Evaluation (MMSE) scale], inflammatory factors (Hypercalcitrance and inflammation factor), and inflammatory factors (Hypercalcitrance and inflammation factor) were compared with those in the other group, inflammatory factors [Hypersensitive C-reactive protein (hs-CRP), interleukin (IL) -1β, IL-6] and TCM evidence score.

Among the 210 patients with CSVD (kidney deficiency and phlegm-stasis type) in this study, 106 cases were included in the study group and 104 cases in the control group. The total effective rate of the study group was higher than that of the basic group, and the difference was statistically significant (P <0.05). Comparison of various scores of cognitive function before treatment between the two groups showed no significant difference (P >0.05), and the MoCA score and MMSE score of patients in the study group were higher than those in the basic group after treatment (P < 0.05). Comparison of inflammatory factors before treatment between the two groups, there was no significant difference (P >0.05), and the levels of hs-CRP, IL-1β and IL-6 were lower than those of the basic group after treatment in the study group (P < 0.05). There was no significant difference between the two groups when comparing the points of Chinese medicine symptoms before treatment (P > 0.05), and the points of symptoms such as diminished intelligence, phlegm, nausea and epigastric distension, and sticky stools were lower than those of the basic group after the treatment in the research group (P < 0.05).

The application of Kongsheng Zhenzhong Pill Modified Formula for CSVD (kidney deficiency, phlegm and stasis type) patients can achieve significant therapeutic effects, improve cognitive function and Chinese medicine symptoms, and reduce the level of inflammatory factors in the patients. The therapeutic effect is superior to that of conventional treatment alone.

To explore the effect of electroacupuncture combined with traditional Chinese medicine fumigation on skin barrier function in patients with moderate to severe atopic dermatitis (AD) of blood deficiency and wind dryness type.

Selected from April 2020 to October 2024, The case data of 96 AD patients admitted to the acupuncture and moxibustion and Massage Department of the First Affiliated Hospital of Xinjiang Medical University were selected, they were randomly divided into two groups, with 48 cases in each group. The control group received Western medicine treatment, while the observation group received electroacupuncture combined with traditional Chinese medicine fumigation treatment. The SCORAD score, skin barrier function indicators, immune function treatment before and after treatment were compared between the two groups, and the clinical efficacy and recurrence rate after 6 months of follow-up and adverse reaction incidence rate were also compared.

After treatment, the water content, sebum content, and interleukin-2 (IL-2) in the stratum corneum of both groups were significantly increased compared to before treatment (P < 0.05). SCORAD scores, transcutaneous water loss (TEWL), eosinophils (EOS), serum immunoglobulin E (IgE), and interleukin-4 (IL-4) were significantly reduced compared to before treatment (P <0.05), and the improvement was more significant in the observation group (P < 0.05). In terms of treatment efficiency, 97.92% in the observation group was significantly better than 81.25% in the control group (P < 0.05) ; The therapeutic effect efficiency was better in the observation group at 97.92% compared to the control group at 81.25% (P <0.05) ; The recurrence rate after 6 months of follow-up was significantly lower in the observation group at 16.67% compared to the control group at 56.25% (P <0.05) ;The incidence of adverse reactions in the observation group (4.17%) was lower than that in the control group (16.67%) (P < 0.05).

The combination of electroacupuncture combined with traditional Chinese medicinal fumigation for treating moderate to severe AD patients with blood deficiency and wind dryness is more effective than using Western medicine alone. It can effectively alleviate symptoms, improve skin barriers, regulate immune function, and prevent recurrence.

To observe the efficacy of Shufeng Zhisou Decoction combined with montelukast sodium in the treatment of patients with cough variant asthma (CVA) and its influence on the airway inflammatory factors levels, pulmonary function and T lymphocyte immune balance.

104 CVA patients with pattern of wind pathogen attacking the lung were selected from September 2023 to July 2024 in Beijing Hepingli Hospital, and were divided into western medicine group (montelukast sodium on the basis of routine treatment) and combined group (Shufeng Zhisou Decoction on the basis of Western medicine group) according to the random number table method, 52 cases in each group. The clinical efficacy, TCM symptoms scores, airway inflammatory factors [fractional exhaled nitric oxide (FeNO), sputum eosinophil (EOS), sputum eosinophil cationic protein (ECP)], pulmonary function [forced vital capacity (FVC), peak expiratory flow (PEF), forced expiratory volume in the first second as a percentage of predicted value (FEV1)] and T lymphocyte immune balance [interleukin-4 (IL-4), interferon-γ (IFN-γ), IFN-γ/IL-4] before and after treatment, adverse reactions and recurrence rate within 1 months of follow-up were compared between groups.

The combined group had higher total effective rate of treatment (90.38% vs 75.00%) than the Western medicine group (P <0.05). After treatment, the scores of cough, expectoration and pharyngeal pruritus in the two groups were decreased (P <0.05), and the scores in combined group [(0.60 ± 0.11) points vs(0.84 ± 0.14) points]、[(0.64 ± 0.11) points vs(0.87 ± 0.14) points]、[(0.68 ± 0.12) points vs(0.79 ± 0.14) points] were lower after treatment (P <0.05). The levels of FeNO, sputum EOS, ECP and serum IL-4 were reduced in both groups after treatment (P <0.05), FVC, PEF, FEV1, IFN-γ and IFN-γ/IL-4 in the two groups were enhanced (P <0.05), and there were statistical differences between groups after treatment (P <0.05).

Shufeng Zhisou Decoction combined with montelukast sodium can effectively improve the clinical symptoms and pulmonary function of CVA, relieve the airway inflammation, regulate the T lymphocyte immune imbalance, and improve the prognosis.

To explore the therapeutic effect of Banxia Gualou Xiebai Decoction on patients with qi deficiency and blood stasis syndrome after percutaneous coronary intervention (PCI) for coronary heart disease.

A total of 154 patients with CHD who were treated with PCI in Affiliated Hospital of Gansu Medical College were selected from May 2023 to April 2024, and were randomized into control group (n=77, routine treatment after PCI) and observation group (n = 77, Conventional treatment + Banxia Gualou Xiebai Decoction) by lottery method. The TCM syndromes scores, cardiac function indexes, blood lipid indexes and hemorheological indexes before and after treatment and occurrence of adverse events during treatment were compared between groups.

Compared with the control group, the scores of TCM syndromes in the observation group were lower after treatment (P < 0.05). The LVESV and LVEDP in the observation group after treatment were lower while the LVEF was higher compared to the control group (P < 0.05). The improvements of blood lipid indexes in the observation group were significantly better, which showed that the levels of TC, LDL-C and TG were significantly decreased while the level of HDL-C was significantly increased (P < 0.05). Compared with the control group, the levels of hemorheology indexes were lower in the observation group after treatment (P < 0.05). No significant difference was exhibited in the total incidence rate of adverse reactions between both groups (P > 0.05).

Banxia Gualou Xiebai Decoction can improve the clinical symptoms, cardiac function, blood lipid levels and hemorheological levels of patients with qi deficiency and blood stasis syndrome after PCI for coronary heart disease, and it is safe at the same time.

To explore the clinical efficacy of modified Yanggan Powder combined with Sini Powder in the treatment of chronic hepatitis B (CHB) with liver depression, spleen deficiency, and blood stasis obstructing the collaterals.

A total of 122 CHB patients diagnosed in the Hai'an Traditional Chinese Medicine Hospital from April 2021 to December 2023 were randomly divided into an observation group (n=61) and a control group (n = 61) using a computer-generated random number method. The control group was treated with entecavir, while the observation group received a combination of modified Yanggan Powder and Sini Powder. After 6 months of treatment, the two groups were compared for TCM syndrome scores, liver function, HBV-DNA load, inflammatory factors (IL-1β, IL-6), liver function ultrasound indicators, therapeutic efficacy, and adverse reactions.

After treatment, both groups showed a reduction in TCM syndrome scores, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBiL), HBV-DNA load, IL-1β, and IL-6, with the observation group showing lower values than the control group (P <0.05). Both groups had an increase in albumin (ALB), with the observation group showing a higher increase than the control group. There were no significant changes in the hepatic portal vein diameter, splenic vein diameter, or spleen thickness before and after treatment in both groups (P > 0.05). The therapeutic efficacy rate in the observation group was higher than that in the control group (P <0.05). No serious adverse reactions were observed in either group.

Modified Yanggan Powder combined with Sini Powder is effective in treating HBV with liver qi stagnation, spleen deficiency, and blood stasis obstructing the channels, helping to relieve liver function symptoms, reduce inflammatory responses, and achieve good therapeutic effects.

To investigate the clinical efficacy of ZHU's chiropractic manipulation combined with Jianyao Pill in patients with lumbar disc herniation (LDH) accompanied by liver and kidney deficiency syndrome.

A retrospective analysis was conducted on the clinical data of 201 patients with liver-kidney deficiency type of lumbar disc herniation (LDH) treated at the Cervical-Lumbar Pain Diagnosis and Treatment Center of Changzhou Hospital of Traditional Chinese Medicine between February 2024 and December 2024. Patients were divided into an observation group and a control group based on treatment protocols. The control group (100 cases) received Jianyao Pill therapy, while the observation group (101 cases) received ZHU's spinal manipulation therapy in addition to the control group's treatment. Both groups underwent a 4-week treatment course. Clinical efficacy, lumbar function [modified Oswestry Disability Index (ODI), lumbar flexion range (LFR), and lumbar flexion/extension muscle strength], pain status [Simplified McGill Pain Questionnaire (SF-MPQ), pressure pain threshold (PPT) at tender points], and adverse reaction rates were evaluated.

The total effective rate was significantly higher in the observation group than in the control group (P <0.05). Post-treatment, both groups showed reduced ODI and SF-MPQ scores compared to baseline (P < 0.05), with greater reductions in the observation group (P < 0.05). LFR, lumbar flexion/extension muscle strength, and PPT levels increased in both groups (P <0.05), with higher values in the observation group (P <0.05). No significant difference in adverse reaction rates was observed between groups (P >0.05).

ZHU's chiropractic manipulation combined with Jianyao Pill demonstrates significant efficacy in improving lumbar function and alleviating pain in LDH patients with liver-kidney deficiency syndrome, with a favorable safety profile.